Petros Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Apr 15, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Apr 15, 2026

PTPI$0.07-46.5%Stored close · as of May 21, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PETROS PHARMACEUTICALS, INC.
April 15, 2026	By:	/s/ Fady Boctor
	Name:	Fady Boctor
	Title:	President and Chief Commercial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.

Joshua N. Silverman

Signature	Title	Date
/s/ Fady Boctor	President and Chief Commercial Officer	April 15, 2026
Fady Boctor	(Principal Executive Officer)
/s/ Mitchell Arnold	Vice President of Finance	April 15, 2026
Mitchell Arnold	(Principal Financial and Accounting Officer)
/s/ Joshua N. Silverman	Executive Chairman	April 15, 2026
/s/ Bruce T. Bernstein	Director	April 15, 2026
Bruce T. Bernstein
/s/ Wayne R. Walker	Director	April 15, 2026
Wayne R. Walker

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.